MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Arcà et al. conducted a comparative analysis of national HTA frameworks for digital therapeutics (DTx) assessed in Germany, the UK, and France. By analyzing cross-country HTAs for two digital therapeutic products, the study revealed substantial differences in assessment criteria and evidence requirements. Despite the divergence, there was a shared emphasis on product positioning within the clinical pathway, the appropriateness of chosen comparators, and considerations of usability. Safety received limited attention, but a request is often made for the addition and evaluation of risk-flagging systems.